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CONSPECTUS
Nanotheranostics represents the next generation of medicine, fusing nanotechnology, therapeutics,
and diagnostics. By integrating therapeutic and imaging agents into one nanoparticle, this new
treatment strategy has the potential not only to detect and diagnose disease but also to treat and
monitor the therapeutic response. This capability could have a profound impact in both the
research setting as well as in a clinical setting. In the research setting, such a capability will allow
research scientists to rapidly assess the performance of new therapeutics in an effort to iterate their
designs for increased therapeutic index and efficacy. In the clinical setting, theranostics offers the
ability to determine whether patients enrolling in clinical trials are responding, or are expected to
respond, to a given therapy based on the hypothesis associated with the biological mechanisms
being tested. If not, patients can be more quickly removed from the clinical trial and shifted to
other therapeutic options. To be effective, these theranostic agents must be highly site specific.
Optimally, they will carry relevant cargo, demonstrate controlled release of that cargo, and include
imaging probes with a high signal-to-noise ratio.
There are many biological barriers in the human body that challenge the efficacy of nanoparticle
delivery vehicles. These barriers include, but are not limited to, the walls of blood vessels, the
physical entrapment of particles in organs, and the removal of particles by phagocytic cells. The
rapid clearance of circulating particles during systemic delivery is a major challenge; current
research seeks to define key design parameters that govern the performance of nanocarriers, such
as size, surface chemistry, elasticity, and shape. The effect of particle size and surface chemistry
on in vivo biodistribution of nanocarriers has been extensively studied, and general guidelines
have been established. Recently it has been documented that shape and elasticity can have a
profound effect on the behavior of delivery vehicles. Thus, having the ability to independently
control shape, size, matrix, surface chemistry, and modulus is crucial for designing successful
delivery agents.
In this Account, we describe the use of particle replication in nonwetting templates (PRINT) to
fabricate shape- and size-specific microparticles and nanoparticles. A particular strength of the
PRINT method is that it affords precise control over shape, size, surface chemistry, and modulus.
We have demonstrated the loading of PRINT particles with chemotherapeutics, magnetic
resonance contrast agents, and fluorophores. The surface properties of the PRINT particles can be
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easily modified with “stealth” poly(ethylene glycol) chains to increase blood circulation time, with
targeting moieties for targeted delivery or with radiolabels for nuclear imaging. These particles
have tremendous potential for applications in nanomedicine and diagnostics.
1. Introduction
In 1965, Gordon Moore described the trend that the number of components in integrated
circuits had approximately doubled every year since 1958. This trend has continued today,
enabled by advances in photolithography which has taken the minimum feature size of
transistors down from about 10 μm in 1970 to 0.045 μm today. In biological terms, this
corresponds to going from the size of a red blood cell down to the size of a single virus
particle. For the first time, the top-down nanofabrication technology from the semiconductor
industry is in the size range to be relevant for the design of particle-based technologies
including vaccines, medicines, and imaging agents. Herein we discuss a novel platform
useful for the fabrication of shape and size specific theranostic agents using a particle
nanofabrication technology known as particle replication in nonwetting templates (PRINT).
Nanoparticles have been extensively evaluated for both imaging and drug delivery;
however, recent efforts have been focused on integrating therapeutic agents and imaging
probes into one nanoparticle. Drug delivery and molecular imaging have benefited from
advances in nanotechnology. Nanoparticles are now used for real-time molecularly targeted
biomedical imaging and as nanotherapeutic agents.1–4 This next generation of medical tools
based upon the fusion of therapeutics and diagnostics has been termed theranostics. Using
this treatment strategy, results of diagnostic tests can be used to design the appropriate
targeted therapy as well as monitor the treatment response. In order to improve the efficacy
of treatment and imaging, theranostic particles need to be biocompatible, monodisperse, and
highly site-specific with optimal capability to carry relevant cargo, demonstrate controlled
release of that cargo, and include imaging probes that give a high signal-to-noise ratio.
In the past 20 years, a plethora of nanoparticle delivery systems have been developed from a
diverse array of materials ranging in size from a few tens of nanometers up to a few
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micrometers; these delivery systems include but are not limited to liposomes, micelles,
dendrimers, and polymer particles.5–13 The utilization of nanocarriers for the delivery of
therapeutics has led to a significant decrease in the toxicity of chemotherapeutics in clinical
trials, which highlights the potential that nanoparticle based drug delivery can have on the
improvement of cancer treatment and patient outcomes.14–16
There are many biological barriers in the human body that challenge the efficacy of
nanoparticle delivery vehicles. Examples of these barriers include blood vessel walls,
physical entrapment of the particles in organs, and removal by phagocytic cells. The rapid
clearance of circulating particles during systemic delivery is a major challenge, and research
is being conducted in an effort to define key design parameters that govern the performance
of nanocarriers, such as size, surface chemistry, modulus, and shape. The effect of particle
size and surface chemistry on in vivo biodistribution of nanocarriers has been extensively
studied, and general guidelines have been established; however, literature guidelines
pertaining to the effect of modulus and shape are lacking.17–23 Clearance of particles from
circulation is primarily due to opsonization, a process of protein adsorption that begins
immediately after the particle comes in contact with plasma, the nature and conformation of
the adsorbed proteins dictates the body’s reaction.18 In an effort to limit opsonization,
surface modification of particles with poly-(ethylene glycol) (PEG) can help the particles
evade the reticuloendothelial system which leads to extended circulation times.17,18,24
Surface modifications with targeting ligands are also commonly used to target particles to
various organs and pathological sites to increase drug delivery efficacy.25,26 Discher and
colleagues recently illustrated the dramatic role that size and modulus can play in
nanocarrier function. They reported that flexible filamentous micelles with single
dimensions as long as 8 μm exhibited circulation half-lives of 5 days, which is significantly
longer than that of PEGylated “stealth” spherical liposomes; however, outside of this effort,
the effect of carrier modulus is essentially unexplored.21
Only in the past few years have researchers begun to illustrate the profound effect that shape
can have on cellular internalization, circulation half-life, and biodistribution.22,27–29
Decuzzi, Ferrari, and co-workers have demonstrated through mathematical models that the
shape of carriers traveling through the blood vessels plays an important role in their
margination toward the vessel wall.30,31 They have also demonstrated using theoretical
models that discoidal particles can drift laterally toward the blood vessel wall and can
therefore adhere more strongly to the vascular walls under flow than spherical particles.
Studies have also reported on higher targeting efficiency of nonspherical particles compared
to their spherical counterparts.29,32 Moreover, elongated particles can more effectively
evade internalization by cells of different types as well as frustrate phagocytosis.33
Collectively, these studies demonstrate that variation in particle shape can dramatically
affect biodistribution and consequently the therapeutic efficacy or imaging efficiency.
PRINT
PRINT is a top-down nanofabrication approach capable of generating monodisperse micro-
and nanoparticles with well-defined size, shape, and modulus. The PRINT process has been
described previously, and a schematic is illustrated in Figure 1.8,34–36 Using this method, we
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have fabricated a diverse array of particles ranging from 80 nm to 20 μm, composed of
poly(D-lactic acid) (PLA), PEG hydrogels, and proteins.35–37 We have also demonstrated
the fabrication of stimuli responsive particles fabricated with either disulfide or silyl ether
cross-links.37,38 PRINT particles can carry a diverse array of cargos by incorporating the
cargo into the particle matrix. We have demonstrated the loading of PRINT particles with
chemotherapeutics, magnetic resonance contrast agents, and fluorophores.37–40 Particle
surface properties can be modified by either matrix composition or post functionalization,
therefore allowing particles surfaces to be amenable to functionalization with targeting
moieties for targeted delivery, “stealth” PEG chains to elongate blood circulation time, or
radiolabels for nuclear imaging.40–42 Examples of particles made using the PRINT process
are shown in Figure 2.
2. Nanotherapeutics
Nanoscale drug delivery vehicles are designed to improve the biodistribution and target site
accumulation of systemically applied therapeutic agents. The most effective drug delivery
vehicles are those that are engineered to be biocompatible, be site-specific, have optimal
capability to carry relevant cargo, and demonstrate controlled release of that cargo at the
pathological site. Recent work shows that exceptionally high chemotherapeutic loading is
possible in poly(lactic-co-glycolic acid) (PLGA) PRINT particles.43 A variety of shapes and
sizes were fabricated from PLGA including cylinders, spheres, prolate ellipsoids, and
toroidal particles (Figure 3).
Early systems aimed to improve site specific accumulation by means of enhanced
permeation and retention passive targeting, a nonselective process that occurs due to leaky
tumor vasculature that allows the accumulation of particles of a certain size at the tumor site.
More advanced methods take advantage of active targeting with ligand-based carrier
materials to improve target cell recognition and efficacy of drug delivery. As many cancer
cells over-express the transferrin and epidermal growth factor receptors, the use of ligands
specific to these receptors is an attractive targeting approach for particle based drug delivery
vehicles.44,45 Once the delivery vehicles reach their target, it is important that they release
their cargo in a controlled fashion, and this has been accomplished through the fabrication of
stimuli responsive carriers.5,46 These carriers can either respond to the reducing nature of
the cytosol or the decrease in pH which occurs in endosomes. These stimuli serve as triggers
to break bonds between carrier and cargo or to destabilize the carrier and facilitate diffusion
of its contents.
Stimuli Responsive PRINT Carriers
A number of drug delivery platforms have taken advantage of the reductive intracellular
environment by incorporating disulfide linkages into their carrier matrices, which cleave
intracelluarly to facilitate cargo release.46,51,52 Cubic PRINT particles were fabricated with
and without a reductively labile disulfide cross-linker.37 Doxorubicin (Dox) was physically
entrapped within the polymer matrix, and since Dox is fluorescent, its presence in the
particle was confirmed using fluorescence microscopy. Dox release was monitored over 48
h for particles fabricated with either a disulfide or a triacrylate cross-linker and release was
only observed for disulfide cross-linked particles incubated with dithiothreitol. The release
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of Dox is due to the reduction of the disulfide bonds, which leads to a decrease in the mesh
density of the polymer, making it more porous and allowing the chemotherapeutic to diffuse
out. These particles were further examined for cytotoxicity in HeLa cells. Particles
composed of the triacrylate cross-linker showed minimal cytotoxicity with 80% of cells
remaining viable at the highest dosing.37 Disulfide cross-linked particles on the other hand
were effective at killing HeLa cells with merely 10% of cells remaining viable at the highest
dosing, thus illustrating the activated release of Dox from the particles and the effective
delivery of chemotherapeutics to HeLa cells.
In an effort to generate a series of particles with tunable cargo release characteristics, we
have designed a family of novel, acid labile silyl ether cross-linkers that show exquisite
control over the degradation rates.38 Silyl ethers are one of the most commonly used
protecting groups in organic chemistry due to the ability to adjust their reactivity by altering
the alkyl substituent on the silicon atom. Generally, large or bulky substituents lead to a
more stable material, whereas the addition of a small substituent leads to a material that is
sensitive to acid and base. We have fabricated PRINT microparticles using bifunctional silyl
ethers (BSE), specifically the dimethyl (DMS), diethyl (DES), and diisopropyl (DIS) silyl
ethers which are susceptible to acid catalyzed hydrolysis and thus are ideal for the
fabrication of acid sensitive biomaterials.38 Cubic particles were fabricated with each BSE
cross-linker and degraded under acidic conditions known to exist inside various cellular
compartments. All BSE cross-linked particles preferentially degraded under acidic
conditions, and the rate of degradation was accelerated as the pH decreased; however, the
rate of degradation differed across the BSEs. DES particles degraded 13.6 times slower than
the DMS particles, and the DIS particles were slower by 2 orders of magnitude.38 This
illustrates that, by changing the substituent around the silicon atom, the rate of particle
degradation can be modulated. Intracellular degradation experiments were conducted with
hexnut particles fabricated from the rapidly degrading DMS cross-linker and the
nondegrading di-tert-butyl (DTS) cross-linker. Intracellular degradation of the silyl ether
particles was tracked using laser confocal microscopy where the DMS particles contained a
green fluorescent dye and the DTS particles contained a red fluorescent dye (Figure 4). Both
particles were incubated with HeLa cells for 24 h, it is clear that after cellular internalization
the DTS particles were not altered by the intracellular conditions, whereas the DMS
particles exhibited signs of degradation (Figure 4). We believe that this is a promising
strategy for precisely controlling the delivery of nanoparticle cargo in vivo.
PRINT Particle Internalization and Targeting
It is well documented in the literature that cellular internalization is highly dependent on size
and surface charge.47–49 However, recent results indicate that particle shape also plays an
important role.33,50 We explored the shape effects on cellular internalization by comparing
HeLa cell internalization of cubic and cylindrical PEG hydrogel particles of various sizes.28
Evidence of particle internalization was obtained by flow cytometry, and confocal and
transmission electron microscopy. Cubic particles were fabricated with side lengths varying
from 2 to 5 μm, and the cylindrical particles were fabricated with diameters ranging from 0.5
μm to 200 nm, with aspect ratios ranging from 1 to 3. HeLa cells readily internalized both
the cubic and cylindrical particles with dimensions as large as 3 μm; however, the
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cylindrical particles exhibited higher internalization rates as compared to the cubic particles
(Figure 5).28 The internalization kinetics of the cylindrical nanoparticles by HeLa cells was
dependent on aspect ratio, and particles with high aspect ratios were internalized 4 times
faster than the low aspect ratio particles.
The surface charge of the particles also strongly effected internalization rates, as 84% of
HeLa cells internalized at least one positively charged particle, whereas negatively charged
particles were not internalized to any significant amount. One strategy for increasing the
specificity of targeting was to override the negative surface charge with specific targeting
ligands. We demonstrated this strategy by incubating negatively charged cylindrical PEG-
based PRINT nanoparticles labeled with transferrin receptor antibody (OKT9) or human
holo-transferrin (hTf) with six human tumor cell lines (HeLa, Ramos, H460, SK-OV-3,
HepG2, and LNCaP) overexpressing transferrin receptor (TfR) and a transformed normal
human cell line (HEK 293) with low TfR expression.42 As shown in Figure 6a,
internalization is indeed observed for the negatively charged particles conjugated with the
targeting ligand. Targeting efficiency was found to be dependent on particle concentration,
ligand density, dosing time, as well as surface receptor expression level.42 After incubation
for 4 h, all six tumor cell lines showed at least 80% uptake for particles labeled with either
hTf or OKT9. In contrast, particles modified with control ligands showed less than 10%
uptake. A kinetic study of cellular uptake was performed with four cell lines with different
levels of TfR expression: Ramos > HeLa = H460 > HEK293. Not only did the uptake of
PRINT particles labeled with either hTf or OKT9 increase with incubation time, but the rate
clearly followed the trend of TfR expression level on the cell lines. Viability of the cells
incubated with the targeted nanoparticles was evaluated, and neither the hTf nor the OKT9
labeled particles showed any appreciable toxicity to the HeLa, H460, SK-OV-3, HepG2, or
LNCap cell lines. However, both the hTF and the OKT9 labeled particles showed dose-
dependent toxicity on the Ramos cell line (Figure 6b). It was suggested that the death of
Ramos cells induced by the labeled nanoparticles is due to the multivalent presentation of
the nanoparticle surface ligands instead of non-specific toxicity of the nanoparticles or free
targeting ligand. This work demonstrates the potential of hTf and OKT9 labeled PRINT
nanoparticles as a platform for targeted drug delivery to cancer cells as well as
immunotherapeutic agents for B-cell lymphoma even without an added therapeutic cargo.
Long Circulating Deformable PRINT Particles
It is well established that PEGylating the surface of nanoparticles can provide steric
stabilization and confer “stealth” properties such to increase nanoparticle circulation time;
however, little is known about deformability, which in biology is known to play a significant
role in attenuating and controlling biodistribution.17,24,53 Red blood cells are able to deform
in order to navigate through various biological barriers that would prevent nonflexible
objects from crossing. Some effort has been made with filomicelles to vary the modulus of
micrometer sized carriers, but outside of this effort the role of deformability of carriers is
essentially unexplored.21 Using the PRINT technique, we were able to fabricate particles
with similar size, shape, and deformability characteristics as mouse red blood cells (6 μm in
diameter).54 These red blood cell mimics (RBCMs) were fabricated from hydrogels
composed primarily of 2-hydroxyelthyl acrylate (HEA) cross-linked with poly(ethylene
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glycol) diacrylate (PEGDA). The modulus of the particles was precisely controlled by
varying the amount of cross-linker. In order to track the RBCMs in vivo, a polymerizable
near-IR dye was incorporated into the particle matrix (Figure 7A). Particles were
administered to mice via a tail vein injection and intravital imaging was used to monitor the
RBCMs real-time in the ear vasculature of the mice over a 2 h time span (Figure 7B). This
data was used to calculate the circulation half-lives of the particles, based upon the change
in fluorescence intensity over time. The circulation times of the particles increased with
increasing particle elasticity, with the least flexible RBCMs being cleared 30 times more
rapidly than the most flexible RBCMs.54 A biodistributuion study was conducted with the
RBCMs with varying flexibility. Mice were sacrificed 2 h post injection; blood and tissue
samples were harvested in order to analyze particle accumulation by fluorescence imaging.
Rigid particles were found primarily in the capillary beds in the lungs, whereas the flexible
particles accumulated primarily in the spleen (Figure 8).54 Further studies will be required to
illuminate the capability of these particles to carry and deliver therapeutic payloads;
however, extremely low modulus RBCMs could have therapeutic or imaging applications
for splenic disorders due to their preferential accumulation in this tissue. They also show
great promise for drug delivery applications because of their long circulation times and low
accumulation in the liver.
3. Nanoscale Contrast Agents
Nanoparticles have been explored as scaffolds for imaging probes used in the detection and
monitoring of disease and disease treatment. The same characteristics that make
nanoparticles an excellent platform for drug delivery make them a sought after platform for
diagnostic imaging. Nanoparticle-mediated delivery of imaging probes provides an
opportunity to reduce toxic side effects associated with commonly employed contrast
enhancement agents by improving specific biodistribution and reducing the required dosage.
Since particle-based contrast agents have the ability to carry multiple beacons per particle,
they can also drastically improve the local contrast and increase sensitivity. Current research
is aimed as using these particle-based contrast agents to detect, diagnose, and monitor the
treatment of cancer.55,56 Nanoparticle imaging probes have been used in conjunction with
magnetic resonance imaging (MRI), positron emission tomography (PET), single photon
emission computed tomography (SPECT), and near-infrared (NIR) fluorescence
imaging.57–59 Significant progress has been made in this area where nanoscale contrast
agents have been used to noninvasively assess target site accumulation and to monitor the
real-time biodistribution of nano-particles; however, carriers designed for imaging have
almost always been spherical in shape. Therefore, the effects of carrier shape have been
understudied in this field, they but have gained recent attention with MR and NIR in vivo
imaging using filamentous particles.21,32
PRINT Contrast Agents
In recent studies, we have demonstrated the use of PRINT particles as imaging contrast
agents for NIR optical, MR, and PET imaging.40,54,60 By incorporating a polymerizable
NIR dye within the matrix of PRINT particles, we were able to successfully track the
particles in vivo using fluorescence imaging.54 We also demonstrated the first examples of
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shape and size specific particles for MR imaging.40 We fabricated 2 μm cubic and 200 nm
cylindrical PRINT particles from a PEG hydrogel matrix containing iron oxide. Since the
PRINT technique allows for the systematic control of the iron oxide content without altering
the size or shape of the particles, we were able to vary the weight percent of iron oxide
within the particle. From these experiments, we found that increasing the weight percent of
iron oxide within the particle matrix resulted in a decrease in signal intensity in T2-weighted
phantom studies,40 which is common throughout the literature for MR imaging with iron
oxide nanoparticles.61 Park et al. recently reported that filamentous (or high aspect ratio)
nanoparticles with an iron oxide core represented an improved nanomaterial platform over
their spherical counterparts for targeting and imaging tumors in vivo.32 We have thus begun
investigating the incorporation of iron oxide into filamentous PRINT particles (Figure 9).39
In contrast to encapsulating imaging agents, we were able to modify the surface of PRINT
particles with 64Cu, a long-lived positron emitter useful for micro-PET/CT imaging.60
PRINT particles were designed with amine handles in order to covalently bind DOTA to the
surface of the particles. DOTA is commonly used for binding radioisotopes to polymers and
thus was used to complex 64Cu to the particles.
4. Conclusion
As discussed in this Account, it is becoming increasingly evident that shape and modulus
can have a profound effect on the behavior of delivery vehicles. Therefore, having the
ability to control shape, size, matrix, surface chemistry, and modulus is crucial for designing
successful delivery agents. The PRINT technique allows us to independently control all of
these variables, and using this method we have created monodisperse, and size and shape
specific particles for delivery of chemotherapeutics and imaging agents. Given the wide
range of protocols available to modify PRINT particles, therapeutic and imaging cargos can
be entrapped within the particle matrix and the exterior surfaces can be functionalized with
targeting ligands or imaging agents. Future development will focus on using the PRINT
platform for the codelivery of therapeutics and imaging contrast agents. In this path forward,
we are currently focused on developing methods to attach stealth and/or targeting ligands to
particles, as some of the compositions used for particle fabrication lack good chemical
handles for surface modifications. To this end, we envision the development of a
combinatorial library of shape and size specific long circulating nanoparticles that will have
the ability to efficiently deliver therapeutics and imaging agents to pathological target sites.
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Schematic illustration of the PRINT process. (A) Delivery sheet casting: A true solution
(red) is made and then cast on a PET substrate using a mayer rod. Solvent is removed under
heat, generating a solid state solution film referred to as the delivery sheet, as it will deliver
the composition to the mold. (B) Particle fabrication: a perfluoropolyether elastomeric mold
(green) is brought into contact with a delivery sheet (red), passed through a heated nip
(gray), and split. The cavities of the mold are filled. (C) Particle harvesting: a filled mold is
brought into contact with a high energy film or excipient layer (yellow) and passed through
the heated nip without splitting. After cooling, the mold is removed to reveal an array of
particles on the high-energy film or excipient layer. Reprinted with permission from ref 43.
Copyright 2011 American Chemical Society.
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Scanning electron micrograph images of particles fabricated using the PRINT method: (A)
degradable 2 μm cubic particles; (B) 10 μm magnetic hydrogel boomerangs; (C) 3 μm
hydrogel toroids; (D) 100 × 300 nm hydrogel rods; (E) 200 nm cylindrical hydrogel
particles; (F) 80 × 2000 nm filamentous hydrogel particles. Image (A) is reprinted with
permission from ref 37, and Image (C) is reprinted with permission from ref 8. Copyright
American Chemical Society 2008 and 2009. Image (E) is reprinted with permission from ref
41. Copyright 2007 Elsevier.
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Scanning electron micrographs of PLGA PRINT particles: (A) 80 ×320 nm cylinders, (B)
200 ×200 nm cylinders, (C) 200 ×600 nm cylinders, (D) 1 μm sphere approximates, (E) 2
μm cubes with ridges, and (F) 3 μm particles with center fenestrations. Scale bars: (A) 5 μm,
(B) 4 μm, (C) 3 μm, (D) 10 μm, (E) 3 μm, and (F) 20 μm. Reprinted with permission from
ref 43. Copyright 2011 American Chemical Society.
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Confocal laser scanning micrographs of HeLa cells incubated with rapidly degrading hexnut
particles (green) and nondegrading hexnut particles (red). Micrographs (A–C) highlight the
phases of particle degradation: swelling (a), fragmentation (b), and complete degradation
(c). The nondegradable particles showed no change when exposed to intracellular conditions
(d). Scale bar represents 10 μm for all images. Reprinted with permission from ref 38.
Copyright 2010 American Chemical Society.
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Confocal laser scanning microscopy micrographs of HeLa cells after a 1 h incubation period
at 37 °C with (A) 3 μm cubic, (B) 2 m cubic, (C) 1 × 1 μm cylindrical, and (D) 200 × 200
nm cylindrical particles. Scale bar represents 10 μm in all images. Reprinted with permission
from ref 28. Copyright 2008 National Academy of Science.
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Transferrin receptor-targeted delivery of PRINT nanoparticles to various cancer and
noncancer cell lines. (a) Cellular uptake and (b) cytotoxicity of particles. Reprinted with
permission from ref 42. Copyright 2010 American Chemical Society.
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(A) Fluorescence micrograph of RBC mimics and (B) intravital image of blue vasculature
and red particles.53 Reprinted with permission from ref 54. Copyright 2011 National
Academy of Science.
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Biodistribution of RBCMs 2 h post dosing by percent recovered fluorescence normalized for
tissue weight. Error bars represent one standard deviation, with n = 3 for each case.
Reprinted with permission from ref 54. Copyright 2011 National Academy of Science.
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Transmission electron microscopy images of PRINT particles (A) 80 × 320 nm and (B) 80 ×
2000 nm containing iron oxide nanoparticles. Reprinted with permission from ref 39.
Copyright 2010 American Chemical Society.
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